Fabian Gerlinghaus & Omar Kurdi
Fabian Gerlinghaus, Omar Kurdi
Founded in 2019, Cellares has assembled a world-class team that has created the Cell Shuttle — the first cell therapy manufacturing platform that combines end-to-end automation with high-throughput capacity.
This cost-efficient and scalable technology is resolving the cell therapy manufacturing bottleneck and enabling pharmaceutical companies to meet commercial scale patient demand, thus saving millions of lives.
Cell therapies have proven their potential to cure aggressive types of cancer where traditional treatment methods have failed. Today, these personalized drugs are manufactured using manual methods, which are expensive, prone to operator error, and impossible to scale. Patients who are eligible for FDA approved cell therapies are dying on waiting lists due to the inability of manufacturers to meet patient demand. With hundreds of companies developing thousands of cell therapies, the need for industrial scale manufacturing solutions will become increasingly critical.
Cellares scalable technology resolves this bottleneck and will be the de-facto standard for cell therapy manufacturing. The company is on a mission to enable access to these life-saving treatments for anyone in need.
More On Cellares
Manufacturing the Future of Cell Therapy: Our Series C in CellaresRead More
Building Infrastructure for Healthcare and Life SciencesRead More
Companies that are Moving Entire Industries ForwardRead More
An Infusion of Capital to Bring Innovative Medicine to More PatientsRead More